Simufilam found safe in review of ongoing Alzheimer’s clinical trials
2024年9月26日 · The board’s findings were announced by therapy developer Cassava Sciences, which said in a press release that the company expects to share data from one clinical trial later this year, and from the other by the middle of next year.. The two trials, dubbed RETHINK-ALZ (NCT04994483) and REFOCUS-ALZ (NCT05026177), have collectively enrolled 1,929 people with mild to moderate Alzheimer’s.
Light the world teal for November’s Alzheimer’s Awareness Month
2024年10月31日 · To help advocates get the word out, the AFA has prepared resources including an Alzheimer’s fact sheet and tips for healthy aging.The foundation also is offering images that can be used as cover photos to tell the world about going teal for Alzheimer’s awareness and loving someone with Alzheimer’s.. Alzheimer’s disease is a neurological condition marked by problems with memory and ...
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
2024年7月11日 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...
Blarcamesine sustains benefits in early Alzheimer’s over year: Data
2024年8月1日 · In Alzheimer’s, misfolded proteins build up into toxic clumps that disrupt the normal functioning of nerve cells, leading to brain damage. This slowly impairs memory and thinking skills, and eventually the ability to carry out the simplest tasks in daily life. “People living with early Alzheimer’s disease have the desire to maintain their sense of self for as long as possible,” said ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
2024年2月8日 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
Alzheimer’s blood test gets FDA breakthrough device designation
2024年3月14日 · The test, Simoa p-Tau 217, has the potential to help doctors diagnose Alzheimer’s in people with cognitive decline before the patients show outward signs of the disease. Alzheimer’s begins with the buildup of proteins, which can be detected via imaging tests before symptoms such as memory loss and disorientation appear. “Early detection is crucial in shaping effective care strategies and ...
For Alzheimer's, Dementia Patients, a Water-filled Jelly Drop for...
2022年5月24日 · “In the care home, I really wanted Jelly Drops to tackle dehydration and also to be really fun and engaging and sort of a social tool in the care home as well,” Hornby said in a video interview with Alzheimer’s News Today.. Hornby created the forerunner to Jelly Drops for his master’s graduation project at Imperial College …
Buntanetap found effective, safe in early Alzheimer’s trial: New data
2024年6月27日 · That’s according to new data from a Phase 2/3 clinical trial (NCT05686044) that tested three doses of buntanetap against a placebo in more than 300 patients with the neurodegenerative disease. The new results were announced last week by buntanetap’s developer Annovis Bio.. APOE4 is a genetic variant that has been identified as one of the strongest risk factors for Alzheimer’s.
Modified Kisunla dosing lowers risk of ARIA-E in Alzheimer’s: Study
2024年11月8日 · The modified dosing regimen reduced ARIA-E the most in patients with two copies of the ApoE4 gene variant, which is known to have a high genetic risk for Alzheimer’s. With the modification, 19% of these patients experienced ARIA-E compared with 57% on the standard dosing regimen, lowering their relative risk by 67%, according to Eli Lilly.
Biomarker test to diagnose Alzheimer's wins FDA breakthrough...
2024年5月2日 · The test, developed by Roche in collaboration with Eli Lilly, is intended to support a more accurate Alzheimer’s diagnosis in adults, ages 60 and older, when used with other clinical assessments.. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening or irreversibly debilitating disease.